Prevalence of metabolic syndrome in patients with psychotic disorders in the netherlands

Journal of Clinical Psychopharmacology

Volumn 29, Issue 4, 2009, Pages 399-402

  Schorr, Susanne G ^a   Slooff, Cees J ^b,c   Bruggeman, Richard ^a,c   Taxis, Katja ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b Mental Health Centre Assen   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; OLANZAPINE;

ADULT; CONTROLLED STUDY; FEMALE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NETHERLANDS; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NETHERLANDS; PREVALENCE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; TREATMENT OUTCOME;

EID: 68449095628     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181acceeb     Document Type: Letter

References (12)

1. de Hert MA, van Winkel R, Van Eyck D, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res. 2006;83:87-93.
2. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19-32.
3. Bobes J, Arango C, Aranda P, et al. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res. 2007;90:162-173.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
5. Grundy SM, Brewer HB, Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433-438.
6. Alberti KGM, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet. 2005;366:1059-1062.
7. Cohn T, Prud'homme D, Streiner D, et al. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry. 2004;49:753-760.
8. Hagg S, Lindblom Y, Mjorndal T, et al. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol. 2006;21:93-98.
9. Bos MB, de Vries JH, Wolffenbuttel BH, et al. The prevalence of the metabolic syndrome in the Netherlands: increased risk of cardiovascular diseases and diabetes mellitus type 2 in one quarter of persons under 60. Ned Tijdschr Geneeskd. 2007;151:2382-2388.
10. van Winkel R, van Os J, Celic I, et al. Psychiatric diagnosis as an independent risk factor for metabolic disturbances: results from a comprehensive, naturalistic screening program. J Clin Psychiatry. 2008;69:1319-1327.
11. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.
12. Correll CU, Frederickson AM, Kane JM, et al. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res. 2007;89:91-100.